CD8A and neoplasm: In anti-PD-1-treated mice, CXCR3 and its ligands are essential in generating CD8+ T lymphocyte responses, and the production of CXCL9 promotes anti-PD-1-induced anti-tumor responses, suggesting that CXCR3 facilitates the interaction between DCs and T lymphocytes in the TME.